Bach / Good Clinical Immunobiology

1. Auflage 2014
ISBN: 978-1-4832-1633-1
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band Volume 2, 330 Seiten, Web PDF

Reihe: Clinical Immunobiology

Clinical Immunobiology, Volume 2 covers the advances in the field being made to apply bone marrow transplantation to the treatment of several diseases. This volume is divided into 11 chapters and begins with surveys of the clinical considerations of bone marrow transplantation. Considerable chapters are devoted to the application of this transplantation to the treatment of various diseases, including aplastic anemia, aregenerative pancytopenia, leukemia, uniformly fatal severe combined immunodeficiency diseases, and Wiskott-Aldrich syndrome. Other chapters examine the cellular engineering in the form of bone marrow and thymus transplantation. The remaining chapters consider the effects of exposure to excessive amounts of radiation or cytotoxic chemicals, as well as the hematopoietic failure based on malfunction of the complex process of normal hematological development and maintenance. This book will be of great value to clinical immunobiologists, practicing physicians, researchers, and medical and biology students.

Autoren/Hrsg.

Bach, Fritz H.

Good, Robert A.

Inhaltsverzeichnis

1;Front Cover;1
2;Clinical Immunobiology;4
3;Copyright Page
;5
4;Table of Contents;6
5;List of Contributors;12
6;Preface;14
7;Contents of Volume 1;18
8;Chapter 1. Bone Marrow Transplantation;20
8.1;I. Introduction;21
8.2;II. Terminology;23
8.3;III. Technique;23
8.4;IV. Histocompatibility;24
8.5;V. Preparation of the Recipient;26
8.6;VI. Clinical Results;27
8.7;VII. Special Consideration According to Underlying Disease;30
8.8;VIII. Support for the Patient without Marrow Function;35
8.9;IX. Success or Failure of Engraftment;40
8.10;X. GVH Disease;40
8.11;XI. Immunological Status of Long-Term Survivors of Marrow Transplantation;43
8.12;XII. Infection following Engraftment;44
8.13;XIII. Nature of Tolerance;45
8.14;XIV. Antileukemic Effect (Adoptive Immunotherapy);46
8.15;XV. Malignant Transformation of Donor Cells;47
8.16;XVI. A Look at the Future;48
8.17;References;49
9;Chapter 2. Bone Marrow Transplantation for Aplasias and Leukemias;52
9.1;I. The First Bone Marrow Grafts in Man after Irradiation Exposure;52
9.2;II. Experimental and Clinical Bone Marrow Graft in Leukemia after Irradiation Conditioning ( GVH versus GVL );53
9.3;III. Bone Marrow Graft in Aplasias and Leukemias after ALG Conditioning; Split Lymphocyte Chimerism;64
9.4;IV. Bone Marrow Transplantation using a Combination of ALG and Cyclophosphamide;69
9.5;V. Experimental Research for New Means to Control GVH;71
9.6;References;79
10;Chapter 3. Bone Marrow and Thymus Transplants: Cellular Engineering to Correct Primary Immunodeficiency;82
10.1;I. Lymphoid System Development and the Concept of Two Interacting Immunity Systems;84
10.2;II. Correction of the DiGeorge Syndrome by Thymus Transplantation;90
10.3;III. Bone Marrow Transplants to Correct Immunodeficiency Diseases;96
10.4;IV. Bone Marrow Transplant to Correct SCID;98
10.5;V. Bone Marrow Transplant in Treating the Wiskott-Aldrich ( WA)Syndrome;100
10.6;VI. Aspiration as a Problem in SCID Patients Fully Reconstituted Immunologically by Bone Marrow Transplantation;105
10.7;VII. Efforts to Use Isolated Stem Cells for Immunological Reconstitution in SCID;106
10.8;VIII. Efforts to Use Bone Marrow Transplantation to Correct SCID When a Matched Sibling Donor Is Not Available;107
10.9;IX. Genetic Determination of Histocompatibility Characteristics in Men and Mice;111
10.10;X. Bone Marrow Transplantation to Correct SCID with a Donor Mismatched with Recipient at All HL-A SD Determinants but Matched at the LD Locus Controlling MLC;114
10.11;XI. Correction of Clq Deficiency by Marrow Transplantation in SCID;115
10.12;XII. Relationship of Successful Marrow Transplantations in Aregenerative Anemia and Leukemia to Transplantations Used in SCID;116
10.13;XIII. Correction of SCID by Fetal Liver Transplantation;117
10.14;XIV. New Experimental Observations Relevant to Cellular Engineering in Man;119
10.15;XV. Cellular Engineering and Common Diseases of Man;121
10.16;XVI. Cellular Engineering and Immunodeficiencies Based on DefectiveDevelopment of Biological Amplification Systems;122
10.17;XVII. Immunodeficiencies in Common Human Diseases—A Challenge for Cellular Engineering;124
10.18;XVIII. Nutritional Deprivation and Immunological Deficiency—A Possible Challenge for Cellular or Molecular Engineering;126
10.19;XIX. Aging and Cellular Engineering;126
10.20;Bibliography;127
11;Chapter 4. Selective Immunotherapy withTransfer Factor;134
11.1;I. Introduction;135
11.2;II. Early Beginnings—Viable Cells as Vehicles of TF;136
11.3;III. Histoincompatible Cell Transfer and Graft-versus-Host (GVH) Disease;138
11.4;IV. Viable Lymphocytes versus TFD for Immunotherapy;139
11.5;V. Later Developments—Availability of TFD;140
11.6;VI. The Scope of TFD for Immunological Reconstitution;141
11.7;VII. TFD Immunotherapy of Infectious Disease;143
11.8;VIII. Reconstitution of Congenital Immunodeficiency Diseases with TFD Therapy;149
11.9;IX. TFD and Cancer Immunotherapy;154
11.10;X. Immunotherapy with TF—Unresolved Questions;160
11.11;XI. Conclusion;168
11.12;References;169
12;Chapter 5. Transfer Factor;172
12.1;I. Introduction;173
12.2;II. Preparation of Transfer Factor;174
12.3;III. Evaluation of Cellular Immunity;176
12.4;IV- Technique of Transfor Factor Therapy and Prophylaxis of Infection;181
12.5;V. Wiskott-Aldrich Syndrome;182
12.6;VI. Mucocutaneous Candidiasis;184
12.7;VII. Combined Immunodeficiency Disease;185
12.8;VIII. Infectious Diseases;186
12.9;IX. Diseases of Unknown Etiology;186
12.10;X. Malignancy;187
12.11;XI. Adverse Reactions;188
12.12;XII. Specificity of Transfer;190
12.13;XIII. Potential Uses of Transfer Factor;191
12.14;XIV. Conclusion;193
12.15;References;194
13;Chapter 6. Transfer Factor Therapy in Immunodeficiencies;196
13.1;I. Introduction;197
13.2;II. Preparation of TF;198
13.3;III. Effects in Normal Subjects;200
13.4;IV. Effects in Immunodeficiencies;201
13.5;V. Effects on Clinical Manifestations;204
13.6;VI. Discussion;205
13.7;VII. Summary;207
13.8;References;208
14;Chapter 7. Immunological Surveillance: Pro and Con;210
14.1;I. Historical Introduction;210
14.2;II. Tumor Immunogenicity;212
14.3;Ill. Effects of Minimal Immunity on Nascent Tumors;214
14.4;IV. Experimental Alteration of the Immune Response;217
14.5;V. Experiments of Nature;219
14.6;VI. Miscellaneous Correlations;219
14.7;VII. Tumor Susceptibility and Phylogeny;220
14.8;VIII. General Conclusions;220
14.9;References;221
15;Chapter 8. Serology of Cancer;224
15.1;I. Serological Detection of Antigens Associated with Tumors of Experimental Animals;225
15.2;II. Serological Approaches to the Study of Viral Oncogenesis;230
15.3;III. Serological Detection of Antigens Associated with Human Cancer;237
15.4;IV. Conclusions;249
15.5;Bibliography;250
16;Chapter 9. The Role of Cell-Mediated Immunity in Control and Growth of Tumors;252
16.1;I. Introduction;252
16.2;II. Evidence That Immune Cells Play an Important Role in the Rejection of Tumors Containing TAA;253
16.3;III. Tests for Cell-Mediated Immunity;255
16.4;IV. Demonstration of Cell-Mediated Immunity to Animal Tumors Using in Vitro Techniques;258
16.5;V. Escape Mechanisms from Immunological Surveillance;261
16.6;VI. The "Unblocking" Phenomenon;266
16.7;VII. "Potentiating" and "Arming" Serum Effects;267
16.8;VIII. Cell Types Involved in Host Defense Reactions Against Cancer;268
16.9;IX. Demonstration of Cell-Mediated Immunity to Human Tumors;269
16.10;X. Possible Implications of Tumor Immunology for Cancer Prevention and Therapy;277
16.11;Xl. Conclusion;282
16.12;Acknowledgments;282
16.13;References;282
17;Chapter 10. Experimental Models of Tumor Immunotherapy;284
17.1;I. Nonspecific Stimulation of the Immune Apparatus;286
17.2;II. Active Specific Immunotherapy;289
17.3;III. Adoptive Transfer of Cell-Mediated Immunity;294
17.4;IV. Passive Immunotherapy;297
17.5;V. Passive Transfer of Immunological Mediators;298
17.6;VI. Antiblocking Immunotherapy;299
17.7;VII. Discussion;300
17.8;References;301
18;Chapter 11. Graft versus Leukemia;306
18.1;I. The Problem;306
18.2;II. Conceptual Considerations;307
18.3;III. The Treatment Model—Overview;308
18.4;IV. The Treatment Model—Dissected;310
18.5;V. Recent Experimental Results;320
18.6;VI. Clinical Implications?;323
18.7;VII. Summary;324
18.8;References;325
19;Subject Index;326